Alliance for Pandemic Preparedness

June 14, 2021

Impact of Baseline SARS-CoV-2 Antibody Status on Syndromic Surveillance and the Risk of Subsequent Covid-19 – a Prospective Multicentre Cohort Study

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] The presence of SARS-CoV-2 anti-nucleocapsid antibodies at baseline was associated with almost 80% protection against SARS-CoV-2 re-infection for a period of at least eight months, according to a study of healthcare workers (HCW) in Switzerland. Among 4,818 participants, 144 (3%) were seropositive at baseline. Among 2,713 participants with ≥1 SARS-CoV-2 test during follow-up, 3 of 67 (4.5%) seropositive individuals reported a positive result, compared to 547 of 2,646 (20.7%) seronegative participants (RR=0.22).

Kohler et al. (June 12, 2021). Impact of Baseline SARS-CoV-2 Antibody Status on Syndromic Surveillance and the Risk of Subsequent Covid-19 – a Prospective Multicentre Cohort Study. Pre-print downloaded Jun 14 from https://doi.org/10.1101/2021.06.09.21258422